Company Snapshot
Atara Biotherapeutics, Inc. investment report
Start with ATRA at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.
Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $66.22M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.07M
Average 1.40M
Intrinsic Value
ATRA Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Monitor ATRA
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price alerts
Get notified when ATRA drops below your target
Current price baseline
$6.50
Current price $6.50
Sign in to activate price alerts.
Price History
How has ATRA traded over time?
Review how the market has priced Atara Biotherapeutics, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.
Price history
Dividend-adjusted closing price
Period change
-51.71%
Period high
$18.09
Period low
$4.18
Latest
$6.50
Investment Notes
Capture the investment case
Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.
My notes
Journal entries for ATRA
Sign in to keep notes
Keep your research and decisions in your personal journal.
Fundamental Analysis
Test company quality against your thesis
Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
ATRA Earnings Waterfall · TTM
NASDAQ:ATRA · Revenue to Net Income
Key Ratios
Analysis
$23.1M of revenue converted into -$9.5M of net income for the selected period. Gross margin is 90.7% and net margin is -282.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Revenue Mix
See which products and regions drive the business
Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.
Revenue by segment
Where ATRA earns its revenue, as reported in company filings
This company does not report revenue segments.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $8.4M |
| Other Current | $3.8M |
| Total Current Assets | $12.2M |
| PP&E (Net) | $6.9M |
| Other Non-current | $890.0K |
| Total Non-current Assets | $7.8M |
| Total Assets | $20.0M |
Analysis
Selected assets total $20.0M for Latest. The largest visible component is Cash & Equivalents at $8.4M, about 41.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Test whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$50.9M. FCF conversion is -155.8% of net income. Operating cash flow was -$50.9M, with capex of $0. The largest bridge item is Working Capital at -$104.7M.
Quality Snapshot
Check the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | +23.9% | -6.3% |
Equity | N/A | N/A | N/A | N/A |
Cash | N/A | N/A | -55.0% | -66.1% |
ROIC | N/A | -3.5% | 55.3% | 222.7% |
Analysis
Latest growth is strongest in ROIC at 222.7% and weakest in Cash at -66.1%. Three-year average ROIC is 55.3%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +23.9% | -5.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +1.5% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +6.5% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.9% over three years. Forward estimates point to EBIT at +6.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Management
Judge how Atara Biotherapeutics, Inc. allocates capital
Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.
Capital Efficiency
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
-84.9%
avg -184.8%
ROIC
222.7%
avg -32.4%
ROA
161.5%
avg -178.8%
Analysis
ROIC is currently the strongest return metric at 222.7% versus its period average of -32.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Dividend Record
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Owner Returns
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.00%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.00%
Analysis
Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Insider Activity
Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$5.74M
Sells
13
$3.79M
Net Transaction Value
+$1.95M
Net buying
Most Active
Nguyen AnhCo
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 4, 26Sep 4, 2026 | Cherry Brian N Direct | Buy | $1M$999,993.60 |
| Aug 17, 26Aug 17, 2026 | Nguyen AnhCo Direct | Sell | $40.9K$40,882.74 |
| May 18, 26May 18, 2026 | Nguyen AnhCo Direct | Sell | $47.8K$47,844.56 |
| May 18, 26May 18, 2026 | Grant-Huerta Yanina Direct | Sell | $22K$22,036.44 |
| May 7, 26May 7, 2026 | Panacea Innovation Ltd Indirect | Sell | $3.2M$3,165,020.99 |
| May 7, 26May 7, 2026 | EcoR1 Capital, LLC Indirect | Buy | $4.7M$4,744,255.45 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $121.8$121.85 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $8.1K$8,144.84 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $1.9K$1,915.91 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $508.3$508.30 |
1–10 of 15
Summary
Insiders reported 2 buys worth $5.74M and 13 sells worth $3.79M over the last 12 months. That adds up to net buying of $1.95M. Nguyen AnhCo was the most active insider with 6 transactions.
Leadership
Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Anhco Nguyen | President, Chief Executive Officer & Director | USDÂ 1.07M | 53 | 132.78K | 1.47% |
Alex Chapman | Vice President of Corporate Communications & Investor Relations | — | — | — | — |
Jim Sesic | Senior Vice President of Regulatory Affairs | — | — | — | — |
Kevin G. Sarney | Interim Chief Financial Officer | — | 61 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Alternatives to ATRA
Compare Atara Biotherapeutics, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Analysts
What Wall Street expects from ATRA
Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.
Analyst Targets
See where analysts expect ATRA to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for ATRA.
Analyst Ratings
How analysts rate ATRA today
See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for ATRA.
Company Overview
Understand how Atara Biotherapeutics, Inc. makes money
Ground the financial evidence in the company profile, business description, and key facts.
Key Information
Stock Analysis
Turn the ATRA report into your next decision
Record your conclusion, evidence, and concerns in a structured analysis workspace.
Investment analysis
Turn ATRA research into a decision
Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.
Sign in on the next page to save a private analysis.
Start analysisFAQ
Common questions about ATRA
Resolve the remaining questions before moving into the detailed workspaces.
Explore
Continue your research
Open the detailed valuation, financial, health, and management workspaces.
Continue the stock analysis
Jump to another research area for this company.